13321 related articles for article (PubMed ID: 10338334)
1. The chemoresistance of human malignant melanoma: an update.
Serrone L; Hersey P
Melanoma Res; 1999 Feb; 9(1):51-8. PubMed ID: 10338334
[TBL] [Abstract][Full Text] [Related]
2. Protein kinase C isoenzymes, p53, accumulation of rhodamine 123, glutathione-S-transferase, topoisomerase II and MRP in multidrug resistant cell lines.
Utz I; Gekeler V; Ise W; Beck J; Spitaler M; Grunicke H; Hofmann J
Anticancer Res; 1996; 16(1):289-96. PubMed ID: 8615623
[TBL] [Abstract][Full Text] [Related]
3. Possible role of the multidrug resistance-associated protein (MRP) in chemoresistance of human melanoma cells.
Berger W; Hauptmann E; Elbling L; Vetterlein M; Kokoschka EM; Micksche M
Int J Cancer; 1997 Mar; 71(1):108-15. PubMed ID: 9096673
[TBL] [Abstract][Full Text] [Related]
4. Multifactorial involvement of multidrug resistance-associated [correction of resistance] protein, DNA topoisomerase II and glutathione/glutathione-S-transferase in nonP-glycoprotein-mediated multidrug resistance in human bladder cancer cells.
Kim WJ; Kakehi Y; Yoshida O
Int J Urol; 1997 Nov; 4(6):583-90. PubMed ID: 9477189
[TBL] [Abstract][Full Text] [Related]
5. Chemotherapy induces or increases expression of multidrug resistance-associated protein in malignant melanoma cells.
Ichihashi N; Kitajima Y
Br J Dermatol; 2001 Apr; 144(4):745-50. PubMed ID: 11298532
[TBL] [Abstract][Full Text] [Related]
6. [Drug resistance of malignant melanoma. Mechanisms and possible modulation].
Schadendorf D; Czarnetzki BM
Hautarzt; 1994 Oct; 45(10):678-84. PubMed ID: 8002335
[TBL] [Abstract][Full Text] [Related]
7. The expression of drug resistance gene products during the progression of human prostate cancer.
Sullivan GF; Amenta PS; Villanueva JD; Alvarez CJ; Yang JM; Hait WN
Clin Cancer Res; 1998 Jun; 4(6):1393-403. PubMed ID: 9626455
[TBL] [Abstract][Full Text] [Related]
8. Human melanoma cell lines selected in vitro displaying various levels of drug resistance against cisplatin, fotemustine, vindesine or etoposide: modulation of proto-oncogene expression.
Kern MA; Helmbach H; Artuc M; Karmann D; Jurgovsky K; Schadendorf D
Anticancer Res; 1997; 17(6D):4359-70. PubMed ID: 9494534
[TBL] [Abstract][Full Text] [Related]
9. Membrane transport proteins associated with drug resistance expressed in human melanoma.
Schadendorf D; Makki A; Stahr C; van Dyck A; Wanner R; Scheffer GL; Flens MJ; Scheper R; Henz BM
Am J Pathol; 1995 Dec; 147(6):1545-52. PubMed ID: 7495278
[TBL] [Abstract][Full Text] [Related]
10. Overcoming of multidrug resistance by introducing the apoptosis gene, bcl-Xs, into MRP-overexpressing drug resistant cells.
Ohi Y; Kim R; Toge T
Int J Oncol; 2000 May; 16(5):959-69. PubMed ID: 10762632
[TBL] [Abstract][Full Text] [Related]
11. Role of glutathione, glutathione S-transferases and multidrug resistance-related proteins in cisplatin sensitivity of head and neck cancer cell lines.
Welters MJ; Fichtinger-Schepman AM; Baan RA; Flens MJ; Scheper RJ; Braakhuis BJ
Br J Cancer; 1998 Feb; 77(4):556-61. PubMed ID: 9484811
[TBL] [Abstract][Full Text] [Related]
12. Expression of resistance factors (P-glycoprotein, glutathione S-transferase-pi, and topoisomerase II) and their interrelationship to proto-oncogene products in renal cell carcinomas.
Volm M; Kästel M; Mattern J; Efferth T
Cancer; 1993 Jun; 71(12):3981-7. PubMed ID: 8099529
[TBL] [Abstract][Full Text] [Related]
13. Co-expression of several molecular mechanisms of multidrug resistance and their significance for paclitaxel cytotoxicity in human AML HL-60 cells.
Huang Y; Ibrado AM; Reed JC; Bullock G; Ray S; Tang C; Bhalla K
Leukemia; 1997 Feb; 11(2):253-7. PubMed ID: 9009089
[TBL] [Abstract][Full Text] [Related]
14. Modulation of multidrug resistance in a cancer cell line by anti-multidrug resistance-associated protein (MRP) ribozyme.
Hatanaka H; Abe Y; Naruke M; Asai S; Miyachi H; Kawakami T; Nagata J; Kamochi J; Kijima H; Yamazaki H; Scanlon KJ; Ueyama Y; Nakamura M
Anticancer Res; 2001; 21(2A):879-85. PubMed ID: 11396179
[TBL] [Abstract][Full Text] [Related]
15. Correlations between the activities of 19 standard anticancer agents, antioxidative enzyme activities and the expression of ATP-binding cassette transporters: comparison with the National Cancer Institute data.
Bracht K; Liebeke M; Ritter CA; Grünert R; Bednarski PJ
Anticancer Drugs; 2007 Apr; 18(4):389-404. PubMed ID: 17351391
[TBL] [Abstract][Full Text] [Related]
16. Bcl-2, bax and bcl-xL expression in human sensitive and resistant leukemia cell lines.
Nuessler V; Stötzer O; Gullis E; Pelka-Fleischer R; Pogrebniak A; Gieseler F; Wilmanns W
Leukemia; 1999 Nov; 13(11):1864-72. PubMed ID: 10557064
[TBL] [Abstract][Full Text] [Related]
17. Multidrug resistance-related proteins in primary choroidal melanomas and in vitro cell lines.
van der Pol JP; Blom DJ; Flens MJ; Luyten GP; de Waard-Siebinga I; Koornneef L; Scheper RJ; Jager MJ
Invest Ophthalmol Vis Sci; 1997 Nov; 38(12):2523-30. PubMed ID: 9375571
[TBL] [Abstract][Full Text] [Related]
18. Cytosine arabinoside (ara-C) resistance confers cross-resistance or collateral sensitivity to other classes of anti-leukemic drugs.
Martin-Aragon S; Mukherjee SK; Taylor BJ; Ivy SP; Fu CH; Ardi VC; Avramis VI
Anticancer Res; 2000; 20(1A):139-50. PubMed ID: 10769646
[TBL] [Abstract][Full Text] [Related]
19. Acute myeloid leukemia cells MOLM-13 and SKM-1 established for resistance by azacytidine are crossresistant to P-glycoprotein substrates.
Messingerova L; Imrichova D; Kavcova H; Turakova K; Breier A; Sulova Z
Toxicol In Vitro; 2015 Oct; 29(7):1405-15. PubMed ID: 26009263
[TBL] [Abstract][Full Text] [Related]
20. Cellular mechanisms of multidrug resistance of tumor cells.
Stavrovskaya AA
Biochemistry (Mosc); 2000 Jan; 65(1):95-106. PubMed ID: 10702644
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
